B细胞急性淋巴细胞白血病儿童及年轻成人接受嵌合抗原受体T细胞治疗后的脑MRI改变
单中心回顾性分析16例25岁及以下B-ALL患者CAR-T治疗前后的脑MRI,81%(13/16)出现治疗后脑部异常,以白质信号改变为主(12/16),其中50%(6/12)原有病灶加重、33%(4/12)新发、17%(2/12)不变;有无「加重/新发病灶」两组间CRS分级(p=0.079)与ICANS分级(p>0.99)无显著差异。
要点
- CAR-T治疗后81%(13/16)出现脑MRI异常,最常见为白质信号改变(12/16)。
- 白质病灶中50%(6/12)较治疗前加重、33%(4/12)新发、17%(2/12)不变。
- 有无「加重/新发病灶」与CRS分级(p=0.079)及ICANS分级(p>0.99)无显著关联。
核心结论
- B-ALL儿童及年轻成人CAR-T治疗后常出现脑MRI异常,以白质信号改变为主,且未显示与更高CRS或ICANS分级相关。
研究设计与样本
- 单中心回顾性研究,纳入2015年4月至2023年10月接受CAR-T治疗的25岁及以下B-ALL患者16例(中位年龄16岁,四分位距11-21;男9例、女7例),比较治疗前后脑MRI。
关键影像表现/征象
- 治疗后脑部异常见于81%(13/16)患者,包括白质信号改变12/16、柔脑膜强化1/16、小脑栓塞性梗死1/16。
- 治疗后白质病灶中50%(6/12)为原有病灶加重、33%(4/12)为新发病灶、17%(2/12)较治疗前不变。
诊断标准与关键数值
- MRI异常分为无变化、原有病灶加重或新发病灶三类。
- 记录CAR介导毒性包括细胞因子释放综合征(CRS)与免疫效应细胞相关神经毒性综合征(ICANS)分级。
- 按有无「加重/新发病灶」分组,用Fisher精确检验比较临床与神经系统症状,CRS分级p=0.079、ICANS分级p>0.99。
临床应用与阅片要点
- 治疗后脑MRI常见白质信号改变,阅片时需与治疗前基线对比以区分加重、新发与不变。
- 原文结论认为这些脑MRI异常与CAR相关毒性严重程度不相关,有助于此类患者的临床管理与监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate brain MRI findings in children and young adults after chimeric antigen receptor (CAR) T-cell therapy for B-cell acute lymphoid leukemia (B-ALL) and associate results with clinical and neurological symptoms.
METHODS: We reviewed pre- and post-CAR-T cell therapy brain MRIs of B-ALL patients aged 25 years or younger who underwent therapy between April 2015 and October 2023 at a single institution. MRI abnormalities were categorized as no change, exacerbation of preexisting lesion, or newly developed lesion. Clinical CAR-mediated toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) grades, were recorded. Patients were grouped into those with and without 'exacerbated/new lesion,' and clinical and neurological symptoms were compared using Fisher's exact test.
RESULTS: Sixteen patients with pre- and post-CAR brain MRIs (median age 16 years [interquartile range, 11-21]; 9 males, 7 females) were included in the analysis. Post-CAR brain abnormalities were observed in 81% (13/16) of patients, including white matter (WM) signal changes (12/16), leptomeningeal enhancement (1/16), and cerebellar embolic infarction (1/16). Of the post-CAR WM lesions, 50% (6/12) were exacerbated, 33% (4/12) were newly developed, and 17% (2/12) remained unchanged compared to pre-CAR brain MRI. No difference in CRS (p = 0.079) or ICANS grades (p > 0.99) was observed between patients with and without 'exacerbated/new lesions'.
CONCLUSION: Children and young adults with B-ALL can develop brain MRI abnormalities after CAR T-cell therapy, predominantly WM signal changes. These brain abnormalities did not show an association with higher CRS or ICANS grade.
KEY POINTS: Question Brain MRI findings after chimeric antigen receptor (CAR) T-cell therapy for B-cell acute lymphoid leukemia (B-ALL) and their association with clinical and neurological symptoms are not well understood. Findings Brain MRI abnormalities, mostly white matter changes, were seen in 81% of patients but were not associated with CAR-mediated toxicities. Clinical relevance Brain MRI abnormalities, commonly observed post-CAR T-cell therapy, do not correlate with the severity of CAR-related toxicities, aiding in the clinical management and monitoring of these patients.
引用
- Kim HG, Yeom KW, Vasyliv I, et al. Brain MRI changes in children and young adults with B-cell acute lymphoblastic leukemia following chimeric antigen receptor T-cell therapy. Eur Radiol. 2025. PMID: 40111490. doi:10.1007/s00330-025-11515-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。